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Successful disease modifying drug development for Alzheimer’s disease (AD) has hit a
roadblock with the recent failures of amyloid-based therapies, highlighting the translational
disconnect between preclinical animal models and clinical outcome. Although disease
modifying therapies are the Holy Grail to pursue, symptomatic therapies addressing
cognitive and neuropsychiatric aspects of the disease are also extremely important for the
quality of life of patients and caregivers. Despite the fact that neuropsychiatric problems
in Alzheimer patients are the major driver for costs associated with institutionalization, no
good preclinical animal models with predictive validity have been documented.We propose
a combination of quantitative systems pharmacology (QSP), phenotypic screening and
preclinical animal models as a novel strategy for addressing the bottleneck in both cognitive
and neuropsychiatric drug discovery and development for AD. Preclinical animal models
such as transgene rats documenting changes in neurotransmitters with tau and amyloid
pathology will provide key information that together with human imaging, pathology and
clinical data will inform the virtual patient model. In this way QSP modeling can partially
overcome the translational disconnect and reduce the attrition of drug programs in the
clinical setting. This approach is different from target driven drug discovery as it aims to
restore emergent properties of the networks and therefore likely will identify multitarget
drugs.We reviewexamples on how this hybrid humanizedQSPapproach has been helpful in
predicting clinical outcomes in schizophrenia treatment and cognitive impairment in AD and
expand on how this strategy could be applied to neuropsychiatric symptoms in dementia.
We believe such an innovative approach when used carefully could change the Research
and Development paradigm for symptomatic treatment in AD.
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BACKGROUND
Development of successful medications for Alzheimer’s disease
(AD) is extremely difﬁcult; the Pharmaceutical Research and
Manufacturing Association (PhRMA) estimates that over the last
12 years for every approved AD drug, 34 other drugs have failed
[PhRMA (2012); resulting in an abominable success rate of less
than 3%. All of these drugs passed preclinical animal tests suc-
cessfully to the extent that companies were willing to invest large
resources. There are many possible reasons for this translational
disconnect, including different active metabolites, differences in
afﬁnities between the human and the rat targets, incomplete
pathology in transgene animal models, the lack of genotypes that
drive human variability and the inability to simulate comedication
in preclinical animal models (Geerts, 2009; Markou et al., 2009)].
The search for disease modifying interventions is still the
Holy Grail for AD (Holtzman et al., 2012). Most of the efforts
have been focused on amyloid modulation, in particular gamma-
secretase inhibition, passive vaccination or amyloid immunother-
apy (Salomone et al., 2012) sofar without success (Castellani and
Perry, 2012; Wolfe, 2012). Possible reasons for the failure include
the choice of patient population and therefore new trial designs
have shifted toward early and evenpresymptomaticAD (Ness et al.,
2012). Another problem is the lack of validated biomarker that
forces clinical trialists to use functional readouts or conversion
rates, although efforts are ongoing for both biochemical and imag-
ing biomarkers within the AD neuroimaging initiative (ADNI;
Carrillo et al., 2012). Also the effect of reverting the underlying
pathology might take a long time to manifest itself in functional
readouts such asAlzheimer disease assessment scale-cognitive sub-
scale (ADAS-Cog), making these trials prohibitively long and
costly.
Other disease modifying approaches are actively investigated,
for example antibodies against tau (Panza et al., 2012) and
neuroinﬂammation (Table 1).
In contrast, a few symptomatic approaches have resulted in
statistical signiﬁcant and modest improvements on the func-
tional ADAS-Cog scale. The 5-hydroxytryptamine-6 (5-HT6)
antagonist SB 742457 has shown improvement in a 26 week
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Table 1 | List of failed therapeutic interventions in Alzheimer’s disease over the last 10 years, ordered according to the general mechanism.
Many drugs failed in Phase II proof-of-concept, some failed in Phase III pivotal trials.
Drug Mechanism Clinical Phase
Amyloid-beta modulation
Bapineuzumab Passive vaccination PhIII
Solanezumab Passive vaccination PhIII
Semagecestat Gamma-secretase inhibitor PhII : irreversibly worsens cognition
avagacestat Gamma-secretase inhibitor PhII : irreversibly worsens cognition
ponezumab Passive vaccination PhII
Tramiprosate Plaque destabilizer PhIII
Scyllo-inositol Block Abeta accumulation PhII
tarenﬂurbil Abeta lowering agent PhIII
Neuroprotective
Latrepirdine (dimebon) Mitochondrial stabilizer PhIII
PF-04494700 RAGE inhibitor PhII
cevimeline Sensitizes neurons to growth factors PhII
idebenone Anti-oxydant PhII
Ibuprofen, naproxen, rofecoxib Anti-inﬂammatory PhII
Atorvastatin, simvastatin Cholesterol modulation PhII
Leuprolide, neotroﬁn Modulates growth factor PhII
rosiglitazone PPAR agonist PhIII
Sabeluzole, T817-MA Neuroprotectant PhIII
SymptomaticTreatment
H3 antagonism, linopirdine, LU25-109, H4 agonism
(PRX-03140), NS2330, ST101
Neurotransmitter modulator PhII
Ispronicline, TC6683 A4b2 nAchR modulator PhII
CX516 AMPAkine PhII
Eptastigmine, huperzine, metrifonate, phenserine,
physostigmine, propentofylline
AChE inhibitor PhII
MEM1003 L-type Ca channel inhibitor PhII
Milameline, sabcomeline, xanomeline, NGX267 Partial mAChR agonist PhII
MKC-231 Improves cholinergic signalling PhII
SGS-742 GABA-B antagonist PhII
suritozole Inverse GABA agonist PhII
Neﬁracetam, piracetam Cognitive enhancer PhII
Neramexane NMDA antagonist PhII
trial (Maher-Edwards et al., 2010; Maher-Edwards et al., 2011)
and the Envivo EVP6124 alpha7 nicotinic acetylcholine receptor
(nAchR)modulator improvedADAS-Cog to the same extent as the
currently approved acetylcholinesterase inhibitors (AChE-I;
http://www.envivopharma.com/news-item.php?id=43).
Such a symptomatic effect is also important for off-target effects
of possible disease modifying compounds; any off-target phar-
macology that would reduce cognitive performance can lead to
a failed clinical development program, even if the biochemical
effect on the primary target is met. An example is dimebon,
a mitochondrial stabilizer molecule (Eckert et al., 2012) which
shows neuroprotection is preclinical models (Steele et al., 2012),
but failed to show an effect in large phase III trials in AD
(Bezprozvanny, 2010). Close study of its total pharmacology
against the human receptors (Okun et al., 2010) reveals signiﬁcant
dopamine genotype-dependent anti-cognitive off-target effects
that probably signiﬁcantly reduces the clinical signal inADAS-Cog
(Geerts, 2012).
A similar situation can be found with regard to the neuropsy-
chiatric symptoms in AD (Lesser and Hughes, 2006). Behavioral
and psychological symptoms of dementia (BPSD), such as apathy,
agitation, depression, and aggression are driving institutionaliza-
tion and therefore contribute signiﬁcantly to the overall cost of
the disease. The currently approved AChE-I medications slightly
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improve the neuropsychiatric symptoms but it is unclear whether
this is a speciﬁc effect or secondary to a cognitive improvement.
In the absence of speciﬁc drugs for this indication, clinical trials
are performed with drugs that have been approved for other indi-
cations. For instance, a 6 week clinical trial in 67 AD patients with
apathy treated with methylphenidate (Mintzer et al., 2012) sug-
gested a trend for improvement of 2.5 points on the AES (Apathy
evaluation scale), and a signiﬁcant improvement on clinical global
impression of change (CGIC; 3.7 points) and on neuropsychiatric
inventory (NPI).
The ideal treatment combination would be a multi-
pharmacology proﬁle that combines symptomatic improvement
(for instance on the ADAS-Cog scale or NPI) with a disease modi-
fying activity. This can substantially de-risk thewhole research and
development (R&D)project, as clinical trials can be executed using
relatively short durations (26 weeks) and market approval can be
sought based upon symptomatic improvement. Once on the mar-
ket, long-term clinical trials or extensive studies using biomarkers
can be performed to prove the disease modifying effect. This has
the additional advantage that patent life can be used to its full
extent.
This suggests that symptomatic treatment for cognitive or neu-
ropsychiatric problems has an important place in the full Research
and Development portfolio for AD.
PRECLINICAL MODELS FOR COGNITIVE ENHANCERS
Traditional cognitive tests such as object recognition, T-maze,
set shifting, and Morris water maze have been performed for
a long time leading to an impressive literature and a profound
understanding of the (rodent) brain neurophysiology that leads
to the observed outcomes. When coupled with animal models
that reﬂect part of Alzheimer pathology, reversal of a cognitive
deﬁcit can be demonstrated with many candidate drugs. Many of
these same drugs do not work in the clinical setting (Thomsen
et al., 2010). Possible solutions discussed at a recent workshop,
“Improving the utility and translation of animal models for ner-
vous system disorders”, on this topic organized by the Institute
of Medicine (http://www.nap.edu/catalog.php?record_id=13530)
include bringing in aspects of human clinical trial management,
such as power calculations, standard operating procedures, blind-
ing of observers and comedication into the preclinical world in
addition to a more organic integration of quantitative systems
pharmacology.
Another issue is the alignment of preclinical test readouts
and human clinical scales. In the ﬁeld of cognitive impairment
associated with schizophrenia (CIAS), The National Institutes
of Health (NIH)-sponsored meetings between Food and Drug
Administration (FDA), academia and industry led to the adoption
of the clinical Matrics scale and the identiﬁcation of preclinical
animal readouts that would correspond to the different clinical
dimensions (for a review see Young et al., 2009). The recently
launched NewMeds Initiative supports the validation of more rel-
evant readouts in rodent preclinical animal models using touch
screen technology (Bartko et al., 2011) in an attempt to bridge this
translational disconnect.
While many of these ideas will improve the reproducibility of
preclinical animal test within different laboratories, it is unclear
whether this will lead to improved success in the clinical develop-
ment phase. There are still fundamental differences linked to the
choice of rodents as preclinical animal models. For instance in the
ﬁeld of cognition, there is increasing evidence that the excitatory-
inhibitory (e-i) balance in cortical and hippocampal networks is
fundamentally different between primates and rodents (Povysheva
et al., 2008), in that monkey basket interneuron cells have a higher
input resistance and a lower ﬁring threshold, and they generated
more spikes at near-threshold current intensities. In the rodent,
gamma-aminobutyric acid (GABA)ergic neurons represent only
about 15% of all cortical neurons (Beaulieu, 1993), while in the
macaque monkey they represent up to 20% in visual cortex and
25% in other cortical areas (Hendry et al., 1987; Beaulieu et al.,
1992). Different interneuron subtypes with short spike duration
are found in the primate cortex, which is not typical for rodent
adapting cells (Zaitsev et al., 2009). Furthermore, the developmen-
tal shift in GABA(A) receptor alpha subunit expression continues
through adolescence in primate cortex, but not in rodents, sug-
gesting species difference kinetics of GABA neurotransmission
(Hashimoto et al., 2009).
PRECLINICAL MODELS FOR NEUROPSYCHIATRIC
SYMPTOMS IN ALZHEIMER’S DISEASE
While there are many preclinical models and readouts for cog-
nition, there are almost no animal models that are typically
developed for neuropsychiatric behavioral symptoms in demen-
tia. Neuropathological studies indeed suggest a profound and
mostly tangle-driven locus coeruleus (LC) pathology early on in
the disease (Palmer and DeKosky, 1993; McMillan et al., 2011) and
additional LC pathology through treatment of mice with N-(2-
chloroethyl)-N-ethyl-bromobenzylamine (DSP4) can exacerbate
olfactory dysfunction in traditional amyloid precursor protein
(APP) transgene mice (Rey et al., 2012).
The dorsal raphe (DR) also shows neuroﬁbrillary tangle pathol-
ogy (Grinberg et al., 2009) at an early stagewhere entorhinal cortex
pathology is not yet fully established, although an imaging study in
patients suggest that postsynaptic neuronal cell loss occurs before
loss of serotonergic projections (Marner et al., 2012). This is in
line with the observation that DR pathology is observed more in
tauopathy transgene mice than in amyloid-related transgene mice;
for instance DR pathology in the P301L tau transgene mice leads
to serotonin metabolism and breathing activity changes (Menuet
et al., 2011).
This suggests that brainstem pathology in serotonin and nora-
drenergic nuclei, in principle can be observed in speciﬁc tau
transgene animal models and further exacerbated either by neuro-
chemical or behavioralmeans For instance, chronic stress, induced
by isolation and chronic restraint can lead to additionally mono-
amine dysfunction (Jeong et al., 2006; Cuadrado-Tejedor et al.,
2012). However, most behavioral readouts were focused on cog-
nitive impairment rather than mood states. In addition, due to
the emphasis on amyloid-based models, not many studies have
been performed on relevant behavioral readouts in tau transgene
mice.
Possible readouts in preclinical animal models include the
resident-intruder test for aggression; locomotor hyperactivity;
forced swim test and tail suspension test for depression and
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saccharine preference or progressive ratio for reinforcement for
apathy.
This overview suggests thatmono-amine dysfunction is present
in the early stages of the disease, is dominantly tau pathology
driven and can affect the behavioral problems associated with
dementia. This would suggest that in order to develop an R&D
strategy with preclinical animal models requires a shift from
amyloid-based models to tau-based models and from purely cog-
nitive readouts to readouts that probemooddysfunction. However
some transgene APP mouse models also show behavioural distur-
bances, such as the 3xTg-AD model (Sterniczuk et al., 2010) that
might be an interesting animal model as it combines both APP
and tau pathology.
However, even when achieving face-validity at the level of
neuropathology in animal models, possible drug discovery could
still be substantially impaired because of the species differences
in receptor distribution and neuromodulator synapse physiology.
For instance the striatal dopaminergic synapse is substantially dif-
ferent between rodent and primate (Spiros et al., 2010), to the
extent that this led to the clinical failure of the partial D2 ago-
nist bifeprunox, despite the fact that this compound achieved a
higher efﬁcacy in preclinical rodent-based animal models than
the similar successful drug aripiprazole. Also, the distribution
of the 5-HT3R, a receptor involved in negative symptoms in
schizophrenia (Akhondzadeh et al., 2009) and in attention deﬁcit
(Lennertz et al., 2010) is fundamentally different between mice
and men (Hewlett et al., 1998; Marazziti et al., 2001), suggesting
that changes in serotonin tone can lead to very different behavioral
outcome.
QUANTITATIVE SYSTEMS PHARMACOLOGY
The previous discussion suggests that improved translation can be
achieved by developing a hybrid computer-based model that com-
bines the best of preclinical neurophysiology with actual human
imaging, postmortem, and clinical data. Such an approach is based
upon a biophysically realistic computer model of neuronal net-
works that takes into account proper target engagement of central
nervous system (CNS) active drugs and well documented effect
of receptor activation level changes on ion-channel conductances
that ultimatelymodulate neuronal excitability and timingof action
potential generation (Geerts, 2012). In addition calibration of the
biological coupling parameters using the correlation between clin-
ical outcomes and the outcomes of the same drugs in the computer
platform ensures a tight clinical association between model output
and actual anticipated clinical result.
Details of the platform have been described elsewhere (Spiros
et al., 2010; Roberts et al., 2012b). With regard to cognitive disor-
ders, we have used this platform to explain the differential clinical
effect of memantine and apolipoprotein E (APOE) on ADAS-Cog
in Alzheimer patients (Roberts et al., 2012b). The platform also
predicted correctly a completely unexpected phase I outcome in
humans with the lowest dose of a novel symptomatic compound
on scopolamine-induced deﬁcit that was different from what pre-
clinical animal models suggested (Nicholas et al., 2012). This was
caused by a different pharmacology for the human vs. the rodent
targets and the human-speciﬁc dynamics of the neuromodula-
tory transmitter. The higher dose was less accurately predicted;
however, the outcome was substantially better in a subsequent
iteration of the model using the feedback from this trial.
We implemented the human-speciﬁc effects of the catechol-O-
methyl transferase (COMT) Val 158Met genotype (Spiros et al.,
2011) based upon imaging studies in healthy volunteers with the
D1R speciﬁc radiotracer NNC-112 (Slifstein et al., 2008). This
helped to identify dimebon’s off-target effect at the D1R as a strong
driver of cognitive effects of dimebon in AD and to show that
this was further modulated by strong COMTVal158Met genotype
effect on the outcome, possibly explaining one of the reasons for
its failure (Geerts, 2012).
With regard to psychiatric symptoms, the model correctly and
blindly predicted a phase II outcome in the positive and nega-
tive symptoms in schizophrenia (PANSS) total scale for a novel
drug in schizophrenia (Geerts et al., 2012). We predicted an unex-
pected motor side-effect that was not observed in preclinical
animal models, but later conﬁrmed in the clinical trial. In the
same paper, we failed to accurately predict the absolute clini-
cal outcome of a second drug, however, we correctly predicted
the relative clinical performance compared to olanzapine. The
platform also identiﬁed the speciﬁc species difference of striatal
dopaminergic synapses that led to the unexpected clinical failure
of bifeprunox, despite outperforming aripiprazole in preclinical
animal tests (Spiros et al., 2010).
This suggests that using the hybrid approach where preclinical
neuropathology derived from speciﬁc animalmodels in behavioral
disturbance is combined with a quantitative systems pharma-
cology (QSP) model has the capacity to improve the clinical
predictability.
STRATEGY FOR A NOVEL PRECLINICAL MODEL OF
BEHAVIORAL PROBLEMS ASSOCIATED WITH DEMENTIA
We propose to combine preclinical neurophysiology, human
neuropathology, and human clinical data in a mechanism-based
computer model for developing new drugs for the BPSD. We
outline a strategy aimed at (1) documenting better the neu-
ropathological changes in modulatory neurotransmitters in AD
by studying the effects of AD pathology on LC, DR, and ventral
tegmentum area, preferably in transgene rats, (2) comparisonwith
the neuropathology observed in human patients, especially with
regard to functional connections between different brain regions,
(3) build a computer model of these interactions based upon the
human imaging template but informed by the neurophysiological
changes in cellular excitability observed in transgene rats and (4)
identify and calibrate emergent properties of the network model
by simulating various clinical trials with CNS psycho-active drugs
and compare this to the clinical outcomes, and (5) use this virtual
patient model to perform in silico screening.
Below, we expand on different steps.
DERIVING INFORMATION FROM PRECLINICAL ANIMAL MODELS
Preclinical data from transgene rats (Liu et al., 2008) are preferred
because of LC and DR size considerations and because electro-
physiology of the rat striatum can be done in awake animals (Li
et al., 2012). Lentivirus-mediated gene transfer with mutant tau
(Khandelwal et al., 2012) can enhance the pathology in the LC
and DR. The striatal dopamine system is an important part of the
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reward circuit involved in mood regulation, while noradrenergic
amygdala-related electrophysiology changes can be detected. At
the same time, in vivo electrophysiology can be used to document
the downstream functional consequences of this pathology. We
believe electrophysiology readouts are much closer to the behav-
ioral readouts in patients and animals than biochemical changes
and therefore are better suited for translation into the clinical
setting.
HUMAN IMAGING, PATHOLOGY, AND GENETICS
A large number of imaging studies have been performed in the
framework of ADNI. They include morphometric, blood-oxygen
level dependent functional magnetic resonance imaging (BOLD
fMRI), functional connectivity and positron emission tomogra-
phy (PET) imaging modalities (Carrillo et al., 2012). Progress has
been made to delineate the functional brain networks in various
psychiatric conditions (Williamson and Allman, 2012), identi-
fying emotional encoding, representational brain and directed
effort networks that are differentially affected in schizophrenia and
mood disorders and that can function as a starting point for com-
plex model implementation. In addition some genetic markers
have been found to associate with speciﬁc domains of behavioral
disturbance that can further inform the computer model (Proitsi
et al., 2012).
As an example, human imaging studies (Kuhn and Gallinat,
2011) can be used for implementation of a model for nega-
tive symptoms (Geerts et al., 2013). Indeed, in schizophrenia
patients, imaging studies suggest a ventromedial prefrontal cor-
tex (vmPFC) BOLD fMRI activity that is inversely related to
the degree of anhedonia (Harvey et al., 2010; Lee et al., 2012)
associated with a corresponding lower ventral striatum activa-
tion (Juckel et al., 2006). This allows deﬁning the pathological
changes and the relation between brain regional activity and clin-
ical scores on anhedonia scales. Using these imaging data together
with neurophysiology data on glycine dynamics, a model has been
constructed that explores the non-linear dose-response of gluta-
matergic interventions, such as Glycine transporter-1 inhibitor in
negative symptoms in schizophrenia (Geerts et al., 2013).
CORTICAL-SUBCORTICAL COMPUTER MODEL
The model of subcortical circuitry consists of three components:
striatum, striatum mediale-globus pallidus (STM-GP) circuitry,
and thalamus (Figure 2). The striatum is based on a previous
model extended from [58] where we have added receptor effects
for pharmaceutical Research and Development. The STM-GP
circuitry will consist of two segments of the GPe and GPi and the
subthalamic nucleus (STN; Rubin and Terman, 2004). An existing
computational thalamusmodel (Bazhenov et al., 1998) is extended
with receptor effects for pharmaceutical research.
Striatum component
The striatum model simulates the processing capacity of generic
medium spiny neurons (MSN) in the ventral striatum or nucleus
accumbens. The model is described in detail elsewhere (Spiros
et al., 2011). The model for the direct and indirect pathways is
based on the Rubin and Terman (2004) model of STN, GPi, and
GPe. Each nucleus contains 16 of neurons with the following
membrane currents: sodium current (Na), delayed rectiﬁer potas-
sium current (Kdr), T-type calcium current (CaT), L-type calcium
current (CaL), and a leak current (Figure 1). Receptor modulation
of these neurons by dopamine, serotonin, acetylcholine, etc., will
be obtained from the literature.
The STN, GPe, and GPi population is divided in two groups
of eight cells each. Each GPe cell receives inhibitory input from 3
other GPe cells and also receives excitatory input from three STN
cells while Each STN cell receives inhibitory input from3GPe cells.
Each GPi cell is coupled to an inhibitory input from a GPe neuron
and excitatory input from a STN neuron. The thalamocortical
(TC) cells of the thalamus all receive inhibitory input from the
GPi cells. Synaptic couplings are similar to the ones implemented
in the working model.
Thalamus component
The model is based on the circuitry and cellular properties of the
model reported by (Bazhenov et al., 1998) with TC and reticular
(Re) neuronal cell types. The TC neurons are excitatory, glu-
tamatergic relay neurons that pass sensory information to the
cortex, while the Re neurons are inhibitory, GABAergic feed-
back neurons that receive inputs from, and inhibit, TC neurons
(Figure 2). The synaptic interaction between these neuronal types,
and their intrinsic membrane properties, leads to oscillations and
suppression of multiple input signals.
The spiking properties of TC neurons is caused (Traub et al.,
1991) by a fast sodium channel, a fast potassium channel, a
low-threshold Ca channel, a hyperpolarization-activated cation
channel, a potassium A channel, and a potassium leak channel. To
model an RE cell, a fast sodium channel, a fast potassium chan-
nel, a low-threshold Ca channel, and a potassium leak channel are
included. Background noise caused by synaptic bombardment by
excitatory and inhibitory neurons is represented by a stochastic
model (Destexhe et al., 2001) containing two ﬂuctuating conduc-
tances. Muscarinic M2receptor activation increases the maximum
conductance of h channels in TC cells and the maximum conduc-
tance of leak channels in Re cells. Serotonergic 5-HT2A receptor
activation increases the maximum conductance of Leak channels
in Re cells.
CORTICAL NETWORK MODEL FOR COGNITIVE ENHANCEMENT
The cortical network model for cognitive function is described
in detail elsewhere (Roberts et al., 2012b). Basically, we extended
a biophysically realistic model of a network comprised of
four-compartment pyramidal cells and two-compartment GABA
interneurons (Durstewitz et al., 2000; DeFelipe, 2002) with the
receptor physiology of 18 different dopaminergic, serotonergic,
noradrenergic, and cholinergic receptors to a system of 80 four-
compartment pyramidal cells and 40 two-compartment interneu-
rons (Figure 2). An mGluR5-dependent delayed afterdepolariza-
tion current that can increase the spiking rate of pyramidal cells for
several secondswas implemented as an alpha function in themodel
with a time constant similar to the observation in (Sidiropoulou
et al., 2009). In contrast to the original network, 40% of the
interneurons do not synapse with pyramidal cells but form a
small local recurrent network, based on insights from the relative
number of pyramidal cells and interneurons (DeFelipe, 2002).
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FIGURE 1 | Screening can be performed by simulating the pharmacology
of existing drugs from chemical libraries such as the Prestwick library
and identifying these with the greatest beneficial effect on the clinical
outcome.These can then be tested in the preclinical animal model before
they are tested in the clinic. In this way, the drug discovery and development
process can be highly streamlined and made more efﬁcient.
A stimulus is initiated by injecting a current at t = 2000 ms
which starts the ﬁring of the target pyramidal cells. Without fur-
ther stimuli, this synchronized ﬁring pattern goes on for a certain
amount of time before it gets degraded by the background noise
and the interference of the distractor neurons. This time span,
called the working memory span, is usually in the range of 4–10 s
and corresponds to the time a certain pattern is held in working
memory (Levy and Goldman-Rakic, 2000).
A time span, called working memory span, is deﬁned as the
time a synchronous ﬁring in the neurons that are stimulated is
sustainedwithout further stimulation.We ﬁrst divide the time axis
in bins of 200 ms and count the number of neurons ﬁring in that
time window and determine the time points where this number
exceeds M/2, where M is the number of neurons stimulated at
t = 2000 ms. The time difference between these two transition
points is the memory span.
In general, we assume a linear normalized relationship
between receptor activation and biological effect on physiologi-
cal responses such as XeffY = X
A
Y−XCY
XCY
; where XAY and X
C
Y are the
actual activation levels of receptor X subtype Y (for instance 5-
HT6) after treatment (A) and the untreated (healthy) control
levels (C).
The parameters coupling the documented intracellular pro-
cesses with these receptors are further calibrated using the correla-
tion between the effect of therapeutic interventions in the network
and their clinicalworkingmemory performance on theADAS-Cog
scale in Alzheimer’s patients (see below).
Alzheimer’s disease pathology is implemented as a loss of cor-
tical neurons (Ball, 1977) at a rate Neuron_Loss (%/week) and
synapses from pyramidal neurons (Masliah et al., 1989) with a rate
Synapse_Loss (%/week). Both excitatory-excitatory (e-e) and e-i
are eliminated at the same rate, but because there is an additional
pyramidal cell loss, e-e synapses tend to decrease faster.
Reduced cholinergic tone (Davies andMaloney, 1976) is imple-
mented as a free parameter ACh_decrease on all cholinergic
receptors (M1 andM2 mAChR, and α7 and α4β2 nAChR). In addi-
tion we introduce a placebo effect at week 12 using an increase in
general cortical dopaminergic tone (Boileau et al., 2007). The size
of the DA placebo effect is calibrated as well.
LC and DR pathology will be implemented as derived
from human neuropathology data. Basically the decrease in
norepinephrine (NE) tone as a consequence of noradrenergic
tau pathology will be reduced by a compensatory mechanism
(McMillan et al., 2011), that however, will get smaller as the
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FIGURE 2 | Circuitry and receptor effects for the proposed cortical-basal
ganglia-thalamic model. A working memory subcircuit (Durstewitz et al.,
2000) maintains a burst of activity representing working memory span. Two
types of medium spiny neurons in the striatum (Gruber et al., 2003), D1 and
D2 project inhibitory (−) synapses to GPi (direct pathway) and GPe (indirect
pathway) respectively. The GPe neurons are reciprocally coupled to
themselves and the subthalamic nucleus (STN; Rubin andTerman, 2004; Pirini
et al., 2009). The STN projects excitatory (+) synapses to the GPi and the GPi
projects inhibitory connections to the thalamus (Bazhenov et al., 1998).
Thalamocortical (TC) neurons excite reticular (Re) neurons that reciprocally
inhibit TC. Sensory input excites TC andTC projects to the cortex. All cell
types receive background excitatory and inhibitory ﬂuctuating inputs that
represent random synaptic activity. White rectangles represent membrane
currents and colored ovals represent receptor types.
disease progresses, while DR pathology will be implemented
as a decrease in 5-HT projection density as determined by 2-
dimethylaminomethyl-phenylsulfanylbenzonitrile (DASB) imag-
ing (Marner et al., 2012).
CALIBRATION OF THE NETWORK WITH CLINICAL DATA
For the calibration of the AD cortical network, we collected the
publicly available data from clinical trials in mild-to-moderate AD
patients using ADAS-Cog clinical scales (Ito et al., 2010), together
with reported clinical data on 5-HT6 antagonists (Maher-Edwards
et al., 2011) and placebo data at 78 weeks from tarenﬂurbil
and tramiprosate trials (Gauthier et al., 2009; Green et al., 2009;
Schneider and Sano, 2009). All together 28 different clinical inter-
ventions over four time points (12, 26, 52, and 78 weeks), four
drugs (donepezil, galantamine, rivastigmine, and SB742457) with
up to three doses are used. The correlation between model out-
come and clinical results is about 0.76 (Roberts et al., 2012a,b),
suggesting that the model outcome is able to relatively accurately
predict the functional outcome of new therapeutic agents on the
ADAS-Cog scales.
As for clinical data on neuropsychiatric symptoms in AD, pub-
lished publicly available data on the effect of CNS active drugs on
the NPI can be used to calibrate different subdomains of behav-
ioral disturbance. Many antipsychotics and antidepressants have
been tested in this patient population. Additional clinical scales
include the behavioral pathology in AD rating scale (BEHAVE-
AD), the Cohen-Mansﬁeld Agitation Inventory (CMAI; De Deyn
and Wirshing, 2001), while extrapyramidal symptoms can be
assessed using the extrapyramidal symptom rating scale.
DISCUSSION
This position paper documents the need for drug discovery and
development focused on neuropsychiatric symptoms in AD and
outlines a strategy for a rational approach. The need for innova-
tive therapies that substantially address the behavioral problems
associated with dementia is driven by the fact that these symp-
toms drive a large part of the economic costs associated with
institutionalization.
Target driven discovery paradigms in general have resulted
in disappointing clinical outcomes; in fact a retrospective study
(Swinney and Anthony, 2011) of FDA-approved medications over
the last 10 years and over all indications has found that a majority
of successful drugs have been identiﬁed using phenotypic assays,
despite a tremendous investment in reductionist genomic-based
approaches. While this study does not explicitly mention CNS
indications, it is safe to assume that in these indcations, target-
derived approaches are even less successful. However, a phenotypic
assay for CNS indications likely has a very low throughput and
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includes rodent or non-human primate models. As a notable
exception, the company psychogenics has optimized a rela-
tively high-throughput behavioral screening systems (Brunner
et al., 2002) that is fully automated. However, the limited trans-
lationability of rodent models for psychiatric or neurological
indications seriously hampers the usefulness of these phenotypic
models.
The humanized QSP approach offers the possibility of cir-
cumventing these limitations because it is a hybrid platform
that is heavily populated with human clinical data, calibrated
and validated with clinical outcome tests and as such can pro-
vide a platform with more translational predictability at least for
symptomatic functional interventions, such as neuropsychiatric
symptoms inAD. In addition, the feedback for every prediction the
model makes, can be used to improve the platform in a learn-and
–conﬁrm cycle (Sheiner, 1997).
Once validated, the QSP model can be used to either screen the
effect of the pharmacology of marketed drugs in a repurposing
strategy. The platform can also screen in silico the pharmacology
of large numbers of compounds in the libraries of pharmaceuti-
cal companies once their afﬁnities against human receptors have
been documented. Almost all drugs that have entered clinical tri-
als for many indications and all compounds that have been tested
for CNS indications, probably have their pharmacology against
human receptors tested.
Alternatively the model can be reverse engineered to identify
the optimal proﬁle of a new compound that would improve the
clinical outcome substantially and a drug discovery program can
then be initiated, hopefully resulting in a multi-pharmacology
drug that can be developed in the clinic. A similar project is
currently ongoing in oncology (Merrimack, 2012) here a novel
drug target was identiﬁed using computational modeling and a
drug discovery program driven by this QSP approach resulted
in a new drug that is currently being tested in the clinic. This
is a very rational way to develop new drugs that would address
emergent phenotypic changes rather than being focused on a
single-target.
Additionally this platform can be used to evaluate the off-target
effects of disease modifying small molecules on neurocogni-
tive and neuropsychiatric symptoms. In fact, because functional
clinical scales are the primary end-parameter for any clinical
trial, it would be a pity if a drug that really affects the pri-
mary cause of the disease would fail in the clinic, because of
off-target pharmacology that would signiﬁcantly reduce clinical
readouts. As an example, dimebon’s failure in AD can partially
be attributed to its off-target effects at the dopamine D1 and the
histamine H1 receptor (Geerts, 2012). The QSP platform for cog-
nitive symptoms in AD is offered as a research service (ADDF,
2012; Geerts, 2012) to the Alzheimer Drug Discovery Foundation
network.
In summary this report describes a novel strategy to screen
new drugs for the challenging indication of behavioral distur-
bances associated with senile dementia and for symptomatic
improvement of cognitive symptoms.
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